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Summary.-The response of intramuscularly growing KHT sarcomas to the chemo-
therapeutic agent 1-(2-cloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) alone or
simultaneously with the chemical radio-sensitizer misonidazole (MISO) wasassessed
using either a tumour growth-delay assay or an in vivo-in vitro tumour-excision
assay. Median tumour growth delay following the combination of 20 mg/kg CCNU
and either 0 5 or 1-0 mg/g MISO was 19-5 and 21-5 days, compared to 10 days for this
CCNU dose alone. A similar degree of enhanced tumour response by MISO (factor
of -2 in tumour growth delay) was seen in RIF-1 tumours treated with 20 mg/kg
CCNU plus 1-0 mg/g MISO. Clonogenic cell-survival studies with KHT sarcomas
demonstrated that MISO at doses of0-25, 05 or 1.0 mg/g given simultaneously with a
range of CCNU doses produced dose-modifying factors (DMFs) of 1-9, 2-1 and 2*4
respectively. Normal tissue toxicity assessed by an LD50/7 assay led to DMFs of 1*2
and 1-4 for CCNU doses combined with 0 5 and 1-0 mg/g MISO. Thus in this animal
tumour model the combination of CCNU and MISO appears to lead to a potential
gain by a factor of 1-7.
A SOLID TUMOUR mnay often have an
inadequate blood circulation because the
vascular growth cannot keep pace with
the rapid tumour-cell proliferation. This
condition may lead in tumours to the
presence of hypoxic cells which have been
shown, in a variety of animal tumour
models, to limit the success of single-dose
and fractionated radiotherapy (Siemann
et al., 1977; Hill & Bush, 1978; Denekamp
et al., 1980). Clinical evidence also impli-
cates hypoxic cells as a cause for local
failures in radiotherapy in at least some
human tumours (Bush et al., 1978; Dische,
1979).
Besides potentially limiting the success
of radiotherapy, recent studies in both
multicellular spheroids and animal tum-
ours have indicated that hypoxic cells may
be resistant to conventional chemothera-
peutic agents. Sutherland et al. (1979)
clearly demonstrated thattheresistance to
Adriamycin in spheroids resulted in part
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from a failure of Adriamycin to penetrate
into the hypoxic regions. Further, these
authors showed that even when equal
drug exposures in both the oxic and hyp-
oxic regions were achieved, the hypoxic
cells were still more resistant to this anti-
tumour agent. Some studies in vivo also
have reported preferential sparing of
hypoxic cells by chemotherapeutic agents
(Hill & Stanley, 1975; Hill, 1979). In
addition to the possible sparing ofhypoxic
cells from chemotherapeutic agents due to
their location relative to the blood supply,
such cells often are not cycling (Tannock,
1970) and, therefore, may not be affected
by proliferation-dependent anti-tumour
agents.
One approach to overcoming this poten-
tial problem in the chemotherapy of a
solid tumour is through the combination
ofa chemotherapeutic agent with an agent
which is preferentially toxic to hypoxic
cells. Potential candidates for such com-1). XV. SIEMANN
binations are the chemical radiosensitizers,
such as misonidazole (MISO), which pene-
trate into the hypoxic regions of tuniours
(Rauth et al., 1978) and have been shown
in spheroids to be capable of killing both
cycling and non-cycling hypoxic cells in
the absence of radiation (Sutherland,
1974; Sridhar et al., 1976). Furthermore,
these agents have been demonstrated to
be toxic to hypoxic cells in some mouse
tumours (Brown, 1977; Conroy et al.,
1.980; Denekamp et at., 1980).
Using multicellular spheroids, Suther-
land et al. (1979, 1980) have shown that
such a combination of an anti-tumour
agent and a chemical radiosensitizer can
effectively reduce the number of clono-
genic cells per spheroid beyond the level
obtained using the chemotherapeutic agent
alone. In vivo combinations of chemo-
therapeutic agents and MISO (Clement et
al., 1980; Rose et al., 1981) have also
enhanced tumour responses in some
tumour systems compared to those
achieved with the anti-tumour agents
alone. Because alkylating agents cause
damage through the generation of free-
radical species and there is some evidence
that hypoxic cells in tumours treated with
nitrosoureas may be spared (Hill &
Stanley, 1975) we have initiated studies
to evaluate the in vivo interaction of
alkylating agents with hypoxic cell sensi-
tizers. The present investigation assesses
the in vivo therapeutic potential of com-
bining the hypoxic cell sensitizer MISO
with the conventional chemotherapeutic
agent 1 - (2 -chloroethyl) -3-cyclohexyl- 1 -
nitrosourea (CCNU).
MATERIALS AND METHODS
Ani,nal and tumnour systeni
All studies w,ere done writh 8-14-week-old
femiiale C3H/HeJ mnice obtained from Jackson
Laboratories. Bar Harbor, ME. KHT sarcoma
cells (Kallinan et al., 1967) were passaged in
vivo every 2 weeks and prepared firom solid
tumours by mechanical dissociation (Thom-
son & Rauth, 1974). The RIF-1 tumnour cell
line was inaintained and passaged alternately
betwveen in vitro cell culture and in vivo solid
tumour growth, using the protocol of
Twentyman et at. (1980). In this laboratory
this tumour cell line has essentially the same
growth characteristics, and the plating
efficiencies from cell culture or solid tumour
are 660% and -,20(% respectively. With
both tumour lines, solid tumours wvere
initiated by inoculating 2 x 105 cells i.m. into
the hind limb). After the tumours had grown
to 0-2-(03 g, the animals were allocated to
various groups an(l treated orm kept as con-
trols.
Drug treatneits
Misonidazole (MISO) was dissolved in
phosphate-buffered saline (PBS) at a con-
centration of 20 mg/ml. CCNU was prepared
by dissolving 10 mg of CCNU in 1 ml of abso-
lute ethanol. Imrnediately before injecting thie
mice. 9 ml of a 0.-3% solution of hydroxy-
propyl cellulose in sterile saline was added to
the CCNU stock solution. All injections were
i.p., and all drug combinations were given
simultaneously. Treating animals wvith the
CCNU carrier alone had no effect on tumour
growth or clonogenic cell survival. Giving
animals receiving CCNU, volumes of PBS
equal to those given to mice receiving MISO
(lid not alter the grow%th delay or clonogenic
cell survival from that due to CCNU alone.
Tutnour response
Tumour growth delay.-Following treat-
inent, the size of each tumour-bearing leg was
measured by passing it through a plastic rod
wNith holes of increasing diameter (Siemanti
et al., 1977). The size of the smallest hole
through which the tumour-bearing leg would
pass then was recorded. This size was coni-
verted to tumour meight using a calibration
curve (Siemann et at., 1977; Siemann &
Sutherland, 1980). Tumour-growth delay
then was determined as the delay bet-ween
the control and treated tumours gro-wing to a
weight equal to 4 x the wi-eight at time 0.
Clonogenic cell survivat. KHT sarcoma-
cell survival was assayed 22 h after treat-
ment. The mice were killed by cervical dis-
location, their tunmours excised, and a single-
cell suspension prepared by combined mnechi-
anical and enzymatic dissociation (Thomson
& Rauth. 1974). The cells wvere mixed with
104 lethally irradiated tumour cells in 0-20/o
agar containing alplha-minimum esseintial
medium supplemented -with 10% foetal calf
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serum and plated into 24-well dishes. Two or
three cell concentrations were plated at each
drug dose point. In about 2 weeks the sur-
viving cells formed colonies which were
counted with the aid of a dissecting micro-
scope. Tumour-cell survival after treatment
was calculated as the product of the ratios of
treated and untreated control values of
plating efficiency, tumour weight and cell
yield per tumour.
Normal tissue toxicity
In the normal tissue toxicity studies, the
drugs were prepared and the animals treated
as described for the tumour-response studies.
Toxicity was assessed in both tumour-bearing
and non-tumour-bearing mice by determining
the number of animals which died during the
7-day post-treatment period. From these data
the LD5017 (lethal dose to 50%0 ofthe animals
in 7 days) and confidence intervals were cal-
culated by fitting a logit bioassay (Berkson,
1955) and using Scheffe's discrimination
intervals (Finney, 1971).
RESULTS
Growth delay
In the initial studies, the response of
02-0-3g KHT sarcomas to a single dose
of CCNU given either alone or simul-
taneously with 1.0 mg/g MISO was
assessed by a growth delay assay. Mice
with equal-sized tumours were selected
from a large number of animals, all of
which had been injected with tumour cells
on the same day. The tumour weight of
each animal was then calculated as a
function of time after treatment for the
various protocols. Fig. 1 shows the data
of a representative experiment. As can be
seen, a considerable range of responses in
each treatment group occurred, and some
animals had to be killed for humane
reasons before the tumours of the others
in the same treatment group reached the
desired endpoint size. Consequently, the
use of the mean tumour weight for these
Time after treatment (days)
FIG. 1.--Growth curves for individual KHT sarcomas treated with PBS, CCNU (20 mg/kg) or CCNU
+ MISO (1 0 mg/g).
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groups was unsatisfactory, particularly at
late times after treatment. The median
tumour response, therefore, was used in
the studies with the KHT sarcoma. The
results indicate that when a dose of 1-0
mg/g MISO is given simultaneously with
a 20mg/kg dose of CCNU, the observed
median tumour-growth delay (using the
time to reach 1 g as the endpoint) is
enhanced from 9 to 23 days. This experi-
ment was repeated, and Fig. 2 shows the
pooled results of 3 studies. The various
treatments are compared in Table I using
the Wilcoxon (Mann-Whitney) Rank Test
(Snedecor & Cochran, 1973). MISO alone
did not alter significantly (P> 0.05) the
tumour-growth delay relative to untreated
controls (data not shown). However, this
sensitizer, at both doses tested, clearly
enhanced the response of the KHT
sarcomas to CCNU (C and * versus 0;
Fig. 2). The groups given CCNU in com-
bination with 0 5 or 1-0 mg/g MISO were
found to be significantly different from the
group treated only with CCNU (P < 0 01)
and from each other (P < 0.01) (Table I).
For comparison with the results with
the KHT sarcoma, the response of the
RIF-1 tumour to a 20mg/kg dose of
CCNUgiven either alone or simultaneously
with 1 mg/g of MISO was evaluated.
Since, with the RIF-1 tumour, no differ-
ence between the median and mean
tumour response was detected, the data
shown in Fig. 3 are the mean tumour
weights + s.e. of each group. The results
show that, although this tumour is
apparently considerably more resistant to
CCNU than the KHT sarcoma, the addi-
tion of 1 mg/g of MISO enhances the
observed tumour growth delay after 20
TABLE I.-Tumour response of KHT sarcoma-bearing C3H mice to combinations of
CCNAU and MISO
Treatment
Controlt
CCNU: 20 mg/kg
CCNU: 20 mg/kg+MISO: 0-5 mg/g
CCNU: 20 mg/kg+M1\ISO: 1-0 mg/g
Time (days) for
median tumour to
grow to 4 times
starting weight
3-5 (2.0-5.0)*$
13-5 (12-5-16-0)*
23-0 (20 5-26.0)**
25-0 (22.5-30.0)***
t Mice wlhich were untreated, or given PBS or the CCNU carrier (see text).
I Confidence limits calculated using non-parametric statistics; * = 97% limits on a sample of 21; ** =97o,
limits on a Pample of 10; *** = 95 O limits on a sample of 17.
§ Wileoxon (Alann-XWhitney) Rank Test (Snedecor & Cochran, 1973).
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FIG. 3. RIF-1 tumour wreight as a function
of time after no treatment (*), a single 20
mg/kg dose of CCNU given alone (LiC) or in
simultaneous combination with 1-0 mg/g
MISO (A). Tumour response to a given
treatment, was determined by converting
from a hole-diameter measurement to
tuimour weight using a calibration curve
(Mlethlods). Mean tumour weight + s.e. for
gi-oups of 9 mice are plotted.
tug/kg of CCNU to a similar extent (factor
of - 2) to that seen in the KHT sarcoma
(Fig. 2).
Clonogenic cell survival
The effect of various CCNU doses on
tumour-cell survival in the KHT sarcoma
is illustrated in Fig. 4 (solid symbols).
Also shown is the survival curve when the
CCNU doses are combined simultaneously
with 1 mg/kg of MISO (open symbols).
MISO alone at this dose (1 mg/g) leads to
little or no cytotoxicity in the KHT
sarcoma. The data points have been fitted
by linear regression and give a dose-
modification factor (DMF) of , 2-4.
In order to determine whether the
measured tumour-cell survival (Fig. 4)
was influenced by the carry over and
release ofdrug(s) from the tumour into the
culture medium as has been described for
bleomycin by Twentyman (1977), the
"tumour-halves" experiment was per-
formed (Table II). In this experiment one
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FiG. 4. Tumour cell survival as a function
of CCNU dose given in the absence (solid
symbols) or presence (open symbols) of a
lmg/g dose ofMISO. I)ifferent symbols rep-
resent separate experiments. In each
experiment 1-4 ttumours werepooled ateachl
dose.
halfof a treated tumour and one halfof an
untreated control tumour were plated
separately, while the other two halves of
these tumours were combined before
plating. The expected surviving fraction,
based on the surviving fractions of the
individual halves, was then calculated for
the combined sample, assuming that the
survival of the treated and untreated
halves were independent of each other
when combined. The results (Table II)
show that unlike the studies reported for
bleomycin (Twentyman, 1977; Begg et al.,
1980) which demonstrated a considerable
reduction in the survival level of the com-
bined sample below expectation, in this
study neither the CCNU nor the CCNU+
MISO treated tumour halves appear to
lead to any killing in the untreated control
tumour half.
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TABLE II.-"Tumour halves" experiment
I
-5
10
-6
10
0 0.25 0.5 0.75 1.0
Dose of misonidazole Cmg/g)
FIG. 6. KHT tumour-cell survival as a func-
tion of the MISO dose combined with a
fixed (10 mg/kg) dose of CCNU. Each data
point represents the mean of 3-6 values
+s.e.
Fig. 5 shows the response of KHT
sarcomas to CCNU treatments in the
presence of 0-5 mg/g (solid symbols) or
0-25 mg/g (open symbols) MISO. The data
show that administering 0-5 mg/g MISO
in combination with CCNU is nearly as
effective as the lmg/g dose. For this com-
bination the DMF is 2. 1. When the dose
of MISO is reduced to 0-25 mg/g, the cell-
survival points show considerable scatter,
but still indicate increased tumour-cell
kill compared to CCNU alone. The calcu-
lated DMF is 1-9.
Another way of illustrating the ability
of the sensitizer to enhance tumour-cell
kill when combined with CCNU is to vary
the dose ofMISO at a fixed dose of CCNU.
This is illustrated in Fig. 6 for a CCNU
dose of 10 mg/kg. Initially, tumour-cell
survival drops rapidly from , 10-2 to
3 x 10-5 when the dose of MISO is raised
-I 10
carry-over in excision
SF
combined
Tumour SF Expec- Ob-
w%,t (g) separate ted* served
047 1.0
15 - 045 5.9x 10-3
-- 0-38 1.0
15 0-38 6-5 x 10-4
0-31 1.0
7-5 1 0 0-31 5S1x 10-4
0-52 1.0
7-5 1 0 0-38 2-6x 10-4
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*Expected SF = (SF. Twtc) + (SFtr x Twttr)t
SF(Twt, + Twttr)
t SFc, SFtr, Twt, and Twttr refer to the surviving
fractions and tumour weights of the control and
treated tumours respectively.
10
I0
103 & -2 0
10
CCNU
o CCNU +
misonidazole 5
(1.0 M g/g)
66
0 5 10 15 20 25' 30
CCNU dose (mg/kg)
FiG. 5. Clonogenic cell surv,,ival as a function
of CCNU dose when given simultaneously
with 0-5 mg/g (solid symbols) or 0-25
mg/g (open symbols) of MISO. The
dashed lines shown are taken from Fig. 4
for comparison.
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from 0 to 0*5 mg/g. Further increases in
the dose of MISO (from 0*5 to 1 mg/g) do
lead to additional cell kill, but cell survival
appears to plateau at the higher sensitizer
doses.
Normal tissue toxicity
The effectiveness of any combination of
agents must ultimately be assessed in
terms of normal tissue toxicities. There-
fore, studies were performed to evaluate
the degree to which MISO would enhance
the whole animal toxicity in female C3H
mice treated with single doses of CCNU.
Preliminary experiments designed to
evaluate the LD50/30 (dose lethal to 50%
of the animals in 30 days) in non-tumour-
bearing mice indicated that most of the
deaths occurred within 5-9 days after
drug injection, and no animals died later
than 13 days after treatment. Because of
tumour regrowth, such LD50/30 studies
could not be performed in KHT sarcoma-
bearing animals. The initial studies using
non-tumour-bearing mice did suggest,
however, that a considerable component
of the toxicity observed for CCNU in the
presence or absence ofMISO probably was
IC
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FIG. 7. Effect of 0 5 and 1-0 mg/g doses of
MISO on the 7-day survival of C3H mice
treated with a range of doses of CCNU.
Data are fornon-tumour-bearingmice (open
symbols) as well as for mice bearing 0-2-
0 3g KHT sarcomas (solid symbols). Each
point represents 6-21 mice. Circles: CCNU
alone. Triangles: CCNU+ 05 mg/g MISO.
Squares: CCNU+ 1 mg/g MISO.
gut toxicity. This finding agreed with the
observations ofothers on the normal tissue
toxicityofsingle-dosenitrosourea(Blackett
et al., 1975). Consequently, the effect of
simultaneous MISO and CCNU on the
LD50/7 in both tumour-bearing and non-
tumour-bearing mice was evaluated.
Two doses of MISO were tested. The
results (Fig. 7) indicate that combining
CCNU with 0.5 mg/g MISO reduces the
LD50/7 from 46*4 (44.4-48.6) (95% con-
fidence intervals) to 38-8 (36.9-40.8) mg/
kg. Increasing the administered dose of
MISO to 1 mg/g reduced the LD50/7
further, to 33*6 (31.8-35.9) mg/kg. Thus,
the simultaneous combination of 0*5 and
1 mg/g of MISO with a range of CCNU
doses leads to DMFs of 1*2 and 1*4
respectively. However, these findings re-
flect only one endpoint, and clearly the
effects of the combination CCNU+MISO
on other normal-tissue endpoints such as
peripheral blood white cell counts also will
need to be evaluated.
DISCUSSION
Evidence from studies in 3-dimensional
multicellular spheroids (Sutherland et al.,
1979) and in vivo mouse tumour models
(Hill & Stanley, 1975) has suggested that
hypoxic cells may be spared by some con-
ventional anti-tumour agents. These cells
thus could survive to regrow the tumour
and consequently limit the success of the
chemotherapy. Recently, however, it has
been demonstrated, both in spheroids
(Sutherland et al., 1980) and in solid
tumours (Clement et al., 1980; Rose et al.,
1981) that by combining an anti-tumour
agent with a radiosensitizer which is pre-
ferentially toxic to hypoxic cells, it may
be possible to achieve a greater tumour
response than with the chemotherapeutic
agent alone. Because of these considera-
tions, the effect of combining BCNU (1,3-
bis (2 - chloroethyl) - 1 -nitrosourea) with
MISO or its demethylation product Ro-
05-9963 in the treatment of solid KHT
sarcomas previously has been evaluated in
our laboratories (Mulcahy et al., 1981).
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Various intervals between the chemo-
therapeutic agent and these two sensi-
tizers were studied. The results demon-
strated that (1) in general MISO was a
more effective sensitizer in combination
with BCNU and (2) of the various inter-
vals evaluated, simultaneous MISO and
BCNU not only led to the maximum
tumour response but also was less toxic
in terms of animal deaths. Consequently,
in the present studies MISO was always
administered simultaneously with CCNU.
The effect of such a combination on
0*2-0O3g KHT sarcomas is illustrated in
Figs 1 and 2. The data show that ad-
ministering 1 mg/g MISO simultaneously
with a 20 mg/kg dose of CCNU causes an
additional tumour-growth delay of 11
days beyond that observed for the chemo-
therapeutic agent alone. This is a sub-
stantially larger effect than was observed
in any combination of MISO plus BCNU
(Mulcahy et al., 1981). For example, com-
bining MISO at 1 mg/g with a dose of
BCNUwhich alone gives the same tumour-
growth delay as a 20 mg/kg dose ofCCNU,
adds only 2 days to the tumour-growth
delay. The enhanced tumour response
when CCNU and MISO are combined
(Figs 1 and 2) occurs at doses which cause
no animal lethality. In addition, it can be
seen from Fig. 2 and Table I that reducing
the dose ofMISO from 1.0 to 0 5 mg/g has
little influence on the subsequent enhance-
ment of the tumour growth delay.
The RIF-1 tumour was also investi-
gated in order to determine whether the
enhanced tumour response from the com-
bination of CCNU and MISO was specific
to the KHT sarcoma. Single doses of 20
mg/kg CCNU and 1 mg/g MISO were
combined, and the results (Fig. 3) show
that MISO increases the tumour-growth
delay from 2 to 4 days. The RIF-1
tumour clearly is much more resistant to
CCNU treatment than the KHT sarcoma
(by a factor of 4-5 in tumour growth
delay). This finding agrees with Lelieveld
et al. (1979) who previously reported a
similar difference in resistance between
the RIF-1 tumour and the KHT tumour
when treatments with another nitrosourea
(BCNU) were carried out. Nevertheless,
despite the resistance of the RIF-1
tumour to nitrosourea treatment, the data
(Fig. 3) illustrate that the enhanced
tumour effect from a combination of
CCNU and MISO is not confined to the
KHT sarcoma.
For comparison with the growth-delay
assay, the effectiveness of combinations of
CCNU and MISO in the treatment ofKHT
sarcomas was also assessed in an excision
assay (Figs 4 and 5). As in the former
assay, this assay demonstrates that a
0.5mg/g dose ofMISO is almost as effective
as a Img/g dose when given simultaneously
with CCNU (DMF of 2.1 vs 2.4). Even at
a dose of 0*25 mg/g MISO the enhance-
ment of the tumour response is consider-
able (DMF 1-9). By comparison, in com-
bination with single doses of radiation
the sensitizer enhancement ratio in this
tumour system falls from - 2*2 to - 1-8
to . 1*6 for MISO doses of 1-0, 0-5 and
0-25 mg/g respectively (Rauth et al., 1978).
Thus, it appears that the enhancement of
the tumour cytotoxicity of CCNU by
MISO is comparable to, or greater than,
what has been achieved by MISO in the
KHT tumour model.
However, despite the substantial in-
crease in tumour cell kill due to a com-
bination ofCCNUandMISO, such tumour-
response enhancements clearly must be
viewed with respect to normal tissue
toxicity. In particular it would appear
possible that MISO given in conjunction
with a systemic agent may prove more
toxic than when used as a sensitizer of
localized radiation. It is, therefore, neces-
sary to (1) reduce the dose ofMISO to the
minimum at which an effective tumour
response can be maintained and (2) assess
normal tissue toxicities for various sensi-
tizer doses and various normal tissue end-
points. This approach has been attempted
in the present study. The data of Figs 5
and 6 indicate that considerable enhance-
ment in the tumour response can be ob-
tained in the KHT tumour using MISO
doses near the clinically achievable range.
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The enhancement in tumour-cell kill does
decline with reduced sensitizer doses.
However, when the DMFs for the normal
tissue response (Fig. 7) are compared to
the DMFs for clonogenic tumour-cell
survival (Figs 4 and 5), the potential
gain (DMF for tumour response/DMF
for normal tissue toxicity) appears to
remain relatively constant at a factor of
1-7.
Normal tissue toxicity assays such as
the LD50/7 primarily focus on whether
MISO enhances the normal tissue toxicity
of the chemotherapeutic agent. Clearly
the chemotherapeutic agent may also
affect the sensitizer-induced normal tissue
toxicity. In particular, such a combination
may enhance the neurotoxicity reported
to be the dose limiting factor for nitro-
imidazoles such as MISO (Wasserman et
al., 1979). Studies to assess whether
nitrosoureas enhance neurotoxicity when
given in combination with sensitizers are
presently in progress. Preliminary data
indicate that CCNU (20 mg/kg) does not
significantly enhance MISO induced oto-
toxicity (Conroy & Siemann, in prepara-
tion) and other necessary neurological
endpoints are being evaluated.
In this study MISO given in combina-
tion with CCNU enhanced tumour-cell
kill over CCNU alone (Figs 4 and 5). The
experiments shown in Table II indicate
that release and reutilization of the
agent(s) was not a problem in the tumour-
excision assays. Theferore, the increased
cell kill observed when MISO was added
to the CCNU treatment was not a conse-
quence of increased release of CCNTU into
the culture medium in the presence of
MISO. However, several other possible
mechanisms for the enhanced tumour
response remain. Some of these are: (1)
interference by MISO with the repair of
potentially lethal damage (PLD) due to
CCNU, (2) altered pharmacokinetics and
bioavailability of either the sensitizer, the
chemotherapeutic agent or both, resulting
in increased or extended drug exposures,
(3) independent action of the agents
against different tumour subpopulations
(i.e. CCNU acting against the well-
oxygenated cells and MISO preferentially
killing the hypoxic cells) and (4) inter-
action between the agents as defined by
Steel & Peckham (1979) resulting in
enhancement or tumour sensitization.
Little tumour-cell toxicity occurs in the
KHT sarcoma model after doses of MISO
as large as 1 mg/g. It therefore appears
unlikely, in view of the large tumour
response enhancement even at low doses
of MISO with both the growth delay and
clonogenic cell-survival assays, that the
two agents are simply acting independ-
ently of each other on different tumour-
cell populations. Preliminary evidence in
our laboratories also suggests that the
enhanced tumour responses to the com-
bined treatment with BCNU are not a
consequence of changes in PLD repair,
although at present this possibility cannot
be dismissed for CCNU. Initial pharmaco-
kinetic studies comparing the levels of
MISO in both the serum and KHT
tumours of mice treated with MISO or
BCNU plus MISO have indicated little
difference between the values obtained
under these two treatment conditions
(Mulcahy et al., in preparation). Such
experiments have not been done for
the combination of CCNU and MISO.
However, in view of the findings with
BCNU it appears unlikely that increased
tumour MISO levels after treatment with
the combination of agents would account
for the marked increase in cell kill seen in
the present study; particularly since a
large tumour effect occurs at MISO doses
of 0*25-0*5 mg/g.
Alternatively, it is perhaps more con-
ceivable that MISO alters the pharmaco-
kinetics and bioavailability of CCNU.
Studies to evaluate this possibility are
presently in progress. Finally, the results
(Figs 4 and 5) are suggestive of an inter-
action between CCNU and MISO similar
to that observed between MISO and
radiation. Since one of the agents (MISO)
on its own is virtually ineffective, isobolo-
grams cannot be constructed, and by
Steel & Peckham's (1979) definition the
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observed enhanced tumour effect could
be considered as "sensitization" of the
tumour to CCNU by MISO.
In conclusion, it is clear that the addi-
tion of radiosensitizers to conventional
anti-tumour agents requires further evalut-
ation; particularly with respect to any
potential enhancement of damage to
critical normal tissues. However, the
findings of the present study imply that
such a combination of agents may provide
an effective approach to enhancing the
tumour response and improving therapy.
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